Current status and future perspectives of immunotherapy in bladder cancer treatment
- PDF / 784,463 Bytes
- 22 Pages / 595.276 x 793.701 pts Page_size
- 113 Downloads / 242 Views
rrent status and future perspectives of immunotherapy in bladder cancer treatment Zhangsong Wu 1
1,2†
, Jinjian Liu
1,2†
1,2
, Ruixiang Dai
& Song Wu
1,2,3*
Department of Urological Surgery, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China; 2 Shenzhen Following Precision Medical Institute, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China; 3 Department of Urological Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China Received April 21, 2020; accepted June 23, 2020; published online August 26, 2020
The treatment strategy of bladder cancer has evolved not only through the traditional modalities of surgery and chemotherapy but also by immunotherapy over the past several decades. Immunotherapies such as intravesical Bacillus Calmette-Guérin (BCG) vaccines and immune checkpoint blockades (ICBs) are sometimes used for treating patients with bladder cancer, especially those who develop resistance to conventional first-line treatments such as surgery and chemotherapy. Unfortunately, it is a limited number of individuals that see clinical benefits from this approach, and complicating matters more is that many of these patients suffer severe immune-related adverse events (irAEs). If current momentum continues to result in improved response rates and managed irAEs, immunotherapy could be poised to revolutionize the landscape of urothelial carcinoma therapeutics. bladder cancer, urothelial carcinoma, immunotherapy, predicative biomarkers, adverse events. Citation:
Wu, Z., Liu, J., Dai, R., and Wu, S. (2020). Current status and future perspectives of immunotherapy in bladder cancer treatment. Sci China Life Sci 63, https://doi.org/10.1007/s11427-020-1768-y
Introduction Urothelial carcinoma of the bladder (UCB) is the most prevalent malignancy worldwide with ~430,000 new diagnoses each year (Siegel et al., 2019). Smoking, gender, and age are established risk factors for bladder cancer (Antoni et al., 2017). Based on the clinical TNM classification of malignant tumors, bladder cancer can be categorized into three distinctly different entities including non-muscle-invasive bladder cancer (NMIBC) with high recurrence rate, muscleinvasive bladder cancer (MIBC) with a significant risk of metastasis, and metastatic disease (mUCB) with high mortality (Antoni et al., 2017). Approximately 75% of newly diagnosed patients present with NMIBC, with the rest di†Contributed equally to this work *Corresponding author (email: [email protected])
agnosed with MIBC or mUCB. In general, the 5-year survival rate of NMIBC is up to nearly 90%, but this declines precipitously to no more than 50% in MIBC and less than 15% in mUCB, respectively (Berdik, 2017; Cumberbatch et al., 2018). The treatment paradigm for urothelial carcinoma is thus unique among these three disease states: NMIBC may be managed by transurethral resection of the bladder tumour (TURBT) with or without
Data Loading...
